These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 33270832

  • 1. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
    Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provôt F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Châtelet V, Launay EA, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Frémeaux-Bacchi V.
    Blood; 2021 May 06; 137(18):2438-2449. PubMed ID: 33270832
    [Abstract] [Full Text] [Related]

  • 2. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
    Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V.
    Clin J Am Soc Nephrol; 2017 Jan 06; 12(1):50-59. PubMed ID: 27799617
    [Abstract] [Full Text] [Related]

  • 3. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.
    Am J Kidney Dis; 2016 Jul 06; 68(1):84-93. PubMed ID: 27012908
    [Abstract] [Full Text] [Related]

  • 4. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C.
    Kidney Int; 2016 Mar 06; 89(3):701-11. PubMed ID: 26880462
    [Abstract] [Full Text] [Related]

  • 5. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.
    Clin Exp Nephrol; 2019 Jan 06; 23(1):112-121. PubMed ID: 30039480
    [Abstract] [Full Text] [Related]

  • 6. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
    Menne J, Delmas Y, Fakhouri F, Licht C, Lommelé Å, Minetti EE, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA.
    BMC Nephrol; 2019 Apr 10; 20(1):125. PubMed ID: 30971227
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.
    Bamhraz AA, Rahim KA, Faqeehi HY, Alanazi A.
    Kidney Blood Press Res; 2020 Apr 10; 45(6):939-954. PubMed ID: 33238263
    [Abstract] [Full Text] [Related]

  • 11. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.
    Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM.
    Nephrol Dial Transplant; 2018 Apr 01; 33(4):635-645. PubMed ID: 29106598
    [Abstract] [Full Text] [Related]

  • 12. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.
    Am J Kidney Dis; 2017 Dec 01; 70(6):770-777. PubMed ID: 28821363
    [Abstract] [Full Text] [Related]

  • 13. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.
    Intern Med J; 2015 Oct 01; 45(10):1054-65. PubMed ID: 26247170
    [Abstract] [Full Text] [Related]

  • 14. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
    Kant S, Bhalla A, Alasfar S, Alachkar N.
    BMC Nephrol; 2020 May 20; 21(1):189. PubMed ID: 32434487
    [Abstract] [Full Text] [Related]

  • 15. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
    Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG.
    Am J Nephrol; 2018 May 20; 48(2):96-107. PubMed ID: 30110670
    [Abstract] [Full Text] [Related]

  • 16. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, García A, Mendizabal S, Gavela E, Macía M, Quintana LF, María Romera A, Borrego J, Arjona E, Espinosa M, Portolés J, Gracia-Iguacel C, González-Parra E, Aljama P, Morales E, Cao M, Rodríguez de Córdoba S, Praga M.
    Nephrol Dial Transplant; 2017 Mar 01; 32(3):466-474. PubMed ID: 28339660
    [Abstract] [Full Text] [Related]

  • 17. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
    Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M.
    Am J Kidney Dis; 2014 Oct 01; 64(4):633-7. PubMed ID: 24656451
    [Abstract] [Full Text] [Related]

  • 18. Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.
    Haskin O, Falush Y, Davidovits M.
    Pediatr Nephrol; 2019 Dec 01; 34(12):2601-2604. PubMed ID: 31520126
    [Abstract] [Full Text] [Related]

  • 19. Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report.
    Fontana F, Alfano G, Bardhushi E, Ligabue G, Giovanella S, Neri I, Cappelli G.
    Am J Case Rep; 2019 Oct 04; 20():1460-1465. PubMed ID: 31582717
    [Abstract] [Full Text] [Related]

  • 20. Atypical Hemolytic Uremic Syndrome After Kidney Transplantation: Lessons Learned From the Good, the Bad, and the Ugly. A Case Series With Literature Review.
    Fayek SA, Allam SR, Martinez E, Pan G, Dao A, Rofaiel G.
    Transplant Proc; 2020 Oct 04; 52(1):146-152. PubMed ID: 31924403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.